RxDoctor Payments Data

Kelly Duggin, MD

Family Medicine · Bradenton, FLNPI 1043763865

Payments from drug & device makers

$1,933in general payments, 2019–2025

Across 88 payments — averaging $21.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$463
  • AstraZeneca$436
  • AbbVie$171
  • Lilly USA, LLC$157
  • Pfizer$104
  • Astellas Pharma US Inc$92
  • plus $510 from 17 others

What the payments were for

  • Food & beverage$1,92099%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,933 in reported general payments places this provider in the 75th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$103,505
Medicare patients
371
Services billed
1,171

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide45$47,823
EliquisApixaban38$40,498
OzempicSemaglutide39$39,192
JanuviaSitagliptin Phosphate16$27,671
FarxigaDapagliflozin Propanediol29$24,381
Tresiba Flextouch U-100Insulin Degludec17$17,433
SynthroidLevothyroxine Sodium33$3,871
Atorvastatin Calcium383$2,566
BreynaBudesonide/Formoterol Fumarate16$1,969
Levothyroxine Sodium285$1,883
Rosuvastatin Calcium158$1,650
Potassium Chloride81$1,467
Metoprolol Succinate84$1,377
Zolpidem Tartrate153$1,363
Gabapentin97$1,277

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$157$47,82345 claims
PfizerEliquis$104$40,49838 claims
Novo NordiskOzempic$463$39,19239 claims
MerckJanuvia$28$27,67116 claims
AstraZenecaFarxiga$436$24,38129 claims
AbbVieSynthroid$171$3,87133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Bradenton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →